CABRI Awards $40,000 in Fellowships to Ten Undergraduate Researchers
ANN ARBOR, MI, DECEMBER 2, 2022—Cayman joins the Cayman Biomedical Research Institute (CABRI) in recognizing the ten undergraduate students who have been awarded fellowships by CABRI for the 2022-2023 academic year. The fellowship awards are given to talented undergraduates that are pursuing a research project of their own under the guidance of a faculty mentor.
Undergraduate fellowships are awarded by CABRI on a competitive basis each year to students who have been offered an unpaid research position. “These fellowships provide a valuable opportunity to undergraduates by allowing them to focus on gaining laboratory experience that builds their scientific talent,” said Kourtney Goode, Ph.D., Academic Relations Coordinator at Cayman.
CABRI funds expanded opportunities for emerging scientists and awards research grants to academic scientists that address basic science research objectives with the highest unmet needs. More information about CABRI’s undergraduate fellowships, scholarships, and research funding opportunities is available on the CABRI website.
The 2022 Recipients Are:
|
Addison Thompson |
|
Branwen Jorenby |
|
Caitlyn Bartsch |
|
Christopher Polera |
|
Jeremy Nelson |
|
Laura Clark |
|
McKenna Spencer |
|
Roman Voskoboynikov |
|
Stevie Rieger |
|
Victoria Glass |
About Cayman Chemical
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman Contract Services provides discovery and preclinical development services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 150 highly skilled scientists with expertise in medicinal chemistry, structure-based drug design, complex multi-step organic synthesis, analytical chemistry, sample analysis, and custom assay development. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.
About CABRI
Cayman Biomedical Research Institute (CABRI) is a nonprofit organization which supports research on the rare illnesses and orphan diseases that are often neglected by the corporate pharmaceutical industry and actively pursues new developments that will treat these diseases. To support this endeavor, we offer research grants to specific principal investigators at academic research institutions who have a plan to extend the clinical or preclinical development for these diseases as well as undergraduate grants to assist students to obtain experience in laboratories while performing research that aligns with CABRI’s mission. CABRI also provides scholarships to college-bound students who have lost a parent to SNUC (sinonasal undifferentiated carcinoma) or B cell lymphoma.